Top 50 Biotech Startup Investors in Denmark (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Novo Holdings
VC Fund
|
30 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $8M–$125M |
|
BioInnovation Institute
VC Fund
|
19 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Debt Financing | Biotechnology, Medical, Health Care | $516k–$5.2M |
|
Vaekstfonden
VC Fund
|
16 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $440k–$4.6M |
|
Export and Investment Fund
VC Fund
|
15 | Denmark, United States, United Kingdom | Seed, Series A | Software, Biotechnology, Health Care | $395k–$84M |
|
Seed Capital
VC Fund
|
9 | Denmark, United States, United Kingdom | Seed, Series A | Software, Health Care, SaaS | $515k–$17M |
|
PSV
VC Fund
|
8 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $88k–$4.6M |
|
Nordic Foodtech VC
VC Fund
|
6 | Finland, Sweden, Denmark | Seed, Series A | Biotechnology, Life Science, Water | $549k–$18M |
|
Oskare Capital
VC Fund
|
6 | Italy, Denmark, United Kingdom | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Medical | $1.2M–$5.9M |
|
Sunstone Life Science Ventures
VC Fund
|
6 | Denmark, Sweden, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $5.5M–$52M |
|
Gilde Healthcare
VC Fund
|
5 | United States, The Netherlands, Germany | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $8.8M–$120M |
|
West Hill Capital
VC Fund
|
4 | United Kingdom, Denmark, Germany | Series A, Seed | Software, Health Care, Financial Services | $1.8M–$15M |
|
The Footprint Firm
VC Fund
|
4 | Denmark, Spain, Norway | Seed, Pre-Seed, Series A | Software, Renewable Energy, Energy Management | $730k–$18M |
|
Per Falholt
Angel
|
4 | Denmark | Pre-Seed, Series A, Seed | Biotechnology, Robotics, Biopharma | $5.9M–$20M |
|
ACME Capital
VC Fund
|
4 | United States, Denmark, Canada | Seed, Series A, Series B | Software, Health Care, Mobile | $1.6M–$70M |
|
Ysios Capital
VC Fund
|
4 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.2M–$135M |
|
DSM Venturing
VC Fund
|
4 | United States, Canada, Israel | Series A, Series B | Biotechnology, Health Care, Manufacturing | $3.5M–$32M |
|
VF Venture
VC Fund
|
4 | Denmark, United Kingdom, Iceland | Seed, Series A | Software, SaaS, Biotechnology | $1.2M–$22M |
|
RA Capital Management
VC Fund
|
4 | United States, United Kingdom, Canada | Series B, Series C, Post-IPO Equity | Biotechnology, Health Care, Therapeutics | $27M–$230M |
|
PINC
VC Fund
|
4 | Sweden, Denmark, United Kingdom | Seed, Pre-Seed, Series A | Biotechnology, Food and Beverage, Coffee | $549k–$7.4M |
|
HealthCap
VC Fund
|
4 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $5.7M–$88M |
|
Atlantic
VC Fund
|
3 | Germany, Switzerland, United States | Seed, Pre-Seed, Series A | Software, Health Care, Financial Services | $850k–$32M |
|
Ugly Duckling Ventures
VC Fund
|
3 | Denmark, Sweden, Finland | Pre-Seed, Seed | Software, Information Technology, Artificial Intelligence | $876k–$4.2M |
|
Bioqube Ventures
VC Fund
|
3 | United States, France, Norway | Seed, Series A, Series B | Biotechnology, Therapeutics, Life Science | $4M–$108M |
|
Nicholas Francis
Angel
|
3 | Denmark, United States | Seed, Series A | SaaS, Robotics, Software | $854k–$7.1M |
|
Innovation Fund Denmark
VC Fund
|
3 | Denmark, United States | Grant, Pre-Seed, Seed | Software, Biotechnology, SaaS | $22k–$1.6M |
|
EIR Ventures
VC Fund
|
3 | Denmark, Sweden, United States | Series A, Seed | Biotechnology, Health Care, Therapeutics | $20M–$73M |
|
Sofinnova Partners
VC Fund
|
3 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$102M |
|
Unconventional Ventures
VC Fund
|
3 | Sweden, United Kingdom, Denmark | Seed, Pre-Seed, Series A | Health Care, Software, Wellness | $1M–$18M |
|
Blue Horizon Corporation
VC Fund
|
3 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Food and Beverage, Food Processing, Biotechnology | $450k–$28M |
|
NOON Ventures
VC Fund
|
3 | Denmark | Seed, Series A | Biotechnology, AgTech, Farming | |
|
Thia Ventures
VC Fund
|
3 | United States, France, Denmark | Series A, Seed, Series B | Biotechnology, Health Care, Food and Beverage | $3.3M–$53M |
|
SR One
VC Fund
|
2 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$115M |
|
Steen Riisgaard
Angel
|
2 | Denmark | Pre-Seed | Life Science, Therapeutics, Biotechnology | |
|
Wellington Partners
VC Fund
|
2 | Germany, United States, United Kingdom | Series A, Series B | Health Care, Biotechnology, Medical | $3.1M–$55M |
|
Lundbeckfonden Ventures
VC Fund
|
2 | United States, Denmark, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$95M |
|
Giampaolo Cagnin
Angel
|
2 | Italy, Denmark | Seed, Pre-Seed | Biotechnology, Food and Beverage, Plant-Based Foods | $4.2M–$7.8M |
|
Bruce Linton
Angel
|
2 | Canada, United States, Denmark | Post-IPO Equity, Seed, Pre-Seed | Cannabis, Health Care, Biotechnology | $37k–$53M |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
CAPNOVA
VC Fund
|
2 | Denmark, United States, India | Seed, Pre-Seed | Software, Information Technology, B2B | $147k–$2.4M |
|
Verve Ventures
VC Fund
|
2 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | |
|
Aescap Venture
VC Fund
|
2 | United Kingdom, Austria, Belgium | Series A, Series B | Biotechnology, Pharmaceutical, Chemical | |
|
Industrifonden
VC Fund
|
2 | Sweden, United States, Denmark | Series A, Seed | Software, Biotechnology, Information Technology | |
|
The Yield Lab Europe
VC Fund
|
2 | Ireland, France, United Kingdom | Seed, Series A | AgTech, Agriculture, Biotechnology | $531k–$10M |
|
+ND Capital
VC Fund
|
2 | United States, Switzerland, Denmark | Series B, Series C, Series A | Biotechnology, Health Care, Medical | |
|
Northzone
VC Fund
|
2 | United States, Sweden, United Kingdom | Series A, Series B, Seed | Software, Information Technology, E-Commerce | |
|
Dawn Biopharma
VC Fund
|
2 | Denmark, France, Belgium | Seed, Series A, Series B | Biotechnology, Health Care, Therapeutics | |
|
Novo Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $8.5M–$143M |
|
Balderton Capital
VC Fund
|
2 | United Kingdom, United States, Germany | Series A, Series B, Series C | Software, FinTech, Financial Services | |
|
Newtree Impact
VC Fund
|
2 | Denmark | Seed | Biotechnology | |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
2 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $909k–$33M |
| Access all 50 investors in Denmark Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 314
- Round size: Series A $8M–$100M; Series B $12M–$125M; Series C $30M–$115M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- Tobira Therapeutics — Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associatedinfectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Debt Financing
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 72
- Round size: Pre-Seed $516k–$5.2M; Debt Financing $549k–$1.4M; Convertible Note $549k–$1.5M
- Lead/follow: 90% lead, 10% follow
Portfolio highlights
- Zeta Diagnostics — First-in-class hardware-and-software-as-a-service diagnostics for the 400M suffering from middle ear problems
- Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 196
- Round size: Seed $810k–$4.6M; Pre-Seed $440k–$1.2M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Captego — Unique, high-speed field data capture. Empower your inspectors & surveyors with our unique collection app. Benefit from high quality data to automate reports and data insights.
- LastSwab — LastSwab launched May 2019 through the crowdfunding platform Kickstarter. At $16 a swab, LastSwab is meant to last at least 1,000 uses and is the easy-to-clean, reusable alternative to the abundant waste caused by single-use swabs around the globe. The tip of the swab is made from medical silicone and nylon and comes in a biodegradable case made ofa corn-based material. LastSwab can be easily cleaned using soap and water and is also dishwasher safe. It comes in a standard swab for cleaning and a pointed swab for makeup application. Be the change and #SwabYourHabits.
- Donkey Republic — Donkey Republic is leading bike share service in Europe with footprint in more than 10 key cities in Europe. We operate our locations with partners, and use custom-branded bikes. Our software backbone is developed by us with unique features that ensure we respect public space with our hub-centric service model. At the same time, we maximizepredictability of bike availability and convenience. We pride ourselves in service innovation.
Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 101
- Round size: Seed $395k–$11M; Series A $3.8M–$84M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Akson Robotics — Akson Robotics is a developer of AI and robotics-based products that focus on greener and efficient agriculture through precision farming.
- Aquark Technologies — Aquark Technologies develops atom systems to develop quantum applications, including atomic clocks, sensors, and navigation systems. Aquark develops a technique to miniaturize cold atom systems using unique laser geometry that is based on more than 10 years of proprietary research at the University of Southampton.
- Coalescent Mobile Robotics — Coalescent Mobile Robotics is a robotics company developing mobile robots to automate transportation processes in the mutilple industries.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 180
- Round size: Seed $515k–$4.9M; Series A $3.5M–$17M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $73M in 2021
Portfolio highlights
- Cardlay — Build your own white-label card and expense management solution with Cardlay. Our platform helps banks, fleets, and tech partners launch modern spend management solutions fast.
- Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
- Templafy — Templafy automates documents to remove risk and increase efficiency for over 800 organizations around the world.
PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV Hafnium, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment. Together, we can punch above our weight.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 136
- Round size: Seed $500k–$4.6M; Pre-Seed $88k–$2.5M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $42M in 2020
Portfolio highlights
- Jabbr — Jabbr allows to capture boxing matches with a virtual video production.Its goal is to make video production and advanced performance analytics in combat sports available to anyone with a smartphone.
- Thiax — ThiaX maps the strain and crystallinity in polymer and composite materials using cutting-edge X-ray diffraction (XRD) technology.
- Enerin — Enerin reduces energy consumption and costs through our know-how within energy technology and operation of heating and cooling systems, including industrial heat pumps through our products Thermonitor, HoegTemp, WaveClean, Feedwater systems and Niprox water treatment.
We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food
Show more...Investment focus
- Industry: Biotechnology, Life Science, Water
- Stage:Seed, Series A
- Geography: Finland, Sweden, Denmark
Investor stats
- Total investments: 26
- Round size: Seed $549k–$5.5M; Series A $7.4M–$18M
- Lead/follow: 54% lead, 46% follow
- Last fund: Likely still investing — raised $49M in 2021
Portfolio highlights
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Endless Food — Endless Food Co is a food innovation firm focusing on the junction of pleasure and sustainability. Endless Food Co was pulled together by a common idea that the transition to a greener and more egalitarian future food system will be driven by flavor, and having spent the last decade pioneering sustainable gastronomy
- Happy Plant Protein — Revolutionize plant protein production with Happy Plant Protein's innovative technology, transforming local ingredients into high-quality, sustainable solutions for the food industry.
Oskare Capital is a venture capital firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: Italy, Denmark, United Kingdom
Investor stats
- Total investments: 8
- Round size: Seed $1.2M–$3.9M; Series A $4.8M–$5.9M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 55
- Round size: Series A $5.5M–$43M; Series B $9.6M–$52M
- Lead/follow: 15% lead, 85% follow
- Last fund: May invest from a new fund soon — raised $94M in 2019
Portfolio highlights
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 124
- Round size: Series A $8.8M–$63M; Series B $15M–$120M; Series C $21M–$75M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $786M in 2023
Portfolio highlights
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- ProVerum Medical — The ProVee stent from Proverum Medical uses 3-D geometry which mirrors and engages with the anatomy of the prostate. The system alleviates Lower Urinary Tract Symptoms (LUTS) by opening the prostatic urethra, applying radial force to the prostatic lobes.
- Endovascular Engineering — Endovascular Engineering is a preclinical stage company developing novel mechanical thrombectomy solutions to address peripheral indications.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.
Show more...Investment focus
- Industry: Software, Health Care, Financial Services
- Stage:Series A, Seed
- Geography: United Kingdom, Denmark, Germany
Investor stats
- Total investments: 57
- Round size: Seed $2.6M–$5.9M; Series A $1.8M–$15M
- Lead/follow: 84% lead, 16% follow
Portfolio highlights
- Algiecel — ALGIECEL - Securing CO2 neutrality with carbon capture as a service Microalgae Cultivation – Easily scalable with modular photobioreactorsALGIECEL is transforming CO2 emissions and LED light into microalgae biomass and Oxygen. The company has developed a plug & play photobioreactor that can be stacked and packed as it is fitting intostandard shipping containers. The reactor is easily installable and requires little technical know-how from small and mid-size industrial clients.ALGIECEL has designed a novel business model that transforms the cost challenge of CO2 removal into a profitable business opportunity across the entire value chain through revenue sharing from the microalgae biomass and carbon credit sales.ALGIECEL´s primary target markets for the application of the photobioreactor will be the biogas and fermentation sectors. In these fast-growing industries many sites are too small for large power-to-x projects to reduce CO2 emissions. Here, ALGIECEL aspires to help in solving the CO2 challenge with our modular carbon capture technology and revenue sharing business model.
- Cercare Medical — Cercare Medical designs and develops a software tool for supporting acute stroke management, helping clinicians to evaluate the effect of a stroke. The software draws up the infarct-area within 30 seconds, locate perfusion area from images within 30 seconds and evaluate mismatch and generate a volume number of salvageable tissue. Cercare Medicalwas incorporated in 2013 under the name Combat Stroke and is based in Denmark.
- ATLANT 3D — Micro and nanodevices are built and tested within days instead of months or years.
The Footprint Firm is an advisory and investment company with a sole focus on sustainability.
Show more...Investment focus
- Industry: Software, Renewable Energy, Energy Management
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, Spain, Norway
Investor stats
- Total investments: 23
- Round size: Seed $730k–$5.5M; Pre-Seed $775k–$4M; Series A $4.8M–$18M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- FoodOp — Helping chefs cut food costs, reduce admin work, and drive sustainability. Menu planning, procurement, and reporting in one place.
- LastSwab — LastSwab launched May 2019 through the crowdfunding platform Kickstarter. At $16 a swab, LastSwab is meant to last at least 1,000 uses and is the easy-to-clean, reusable alternative to the abundant waste caused by single-use swabs around the globe. The tip of the swab is made from medical silicone and nylon and comes in a biodegradable case made ofa corn-based material. LastSwab can be easily cleaned using soap and water and is also dishwasher safe. It comes in a standard swab for cleaning and a pointed swab for makeup application. Be the change and #SwabYourHabits.
- Reel Energy — Reel empowers all companies to procure renewable electricity that makes a real difference for the climate.
A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more...Investment focus
- Industry: Biotechnology, Robotics, Biopharma
- Stage:Pre-Seed, Series A, Seed
- Geography: Denmark
Investor stats
- Total investments: 5
- Round size: Series A $5.9M–$20M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
ACME Capital is a venture capital and private equity firm that invests in breakthrough technologies that fuel platform shifts and disruptive business models that capitalize on new platforms. Its purpose is to support those founders who choose to take their capital. The firm was founded in 2018 and headquartered in San Francisco, California.
Show more...Investment focus
- Industry: Software, Health Care, Mobile
- Stage:Seed, Series A, Series B
- Geography: United States, Denmark, Canada
Investor stats
- Total investments: 166
- Round size: Seed $1.6M–$8.6M; Series A $4.4M–$30M; Series B $15M–$70M
- Lead/follow: 21% lead, 79% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Beepi — Beepi is a Los Altos, California company offering an online peer-to-peer marketplace for buying and selling used cars, where transactions can be carried out entirely with a smart phone or a PC. It was launched in April 2014.The Internet has changed everything. Well, not quite. Buying and selling used cars, unfortunately, hasn't changed fordecades. Now that painful world is waking up. It's going from sleepi to Beepi. Beepi replaces the used car lot with a system that connects buyers and sellers in a radical new way.No negotiating, no trips to the dealer, no surprises – and no commission to the guy with the plaid jacket. Which means a better price for everyone. Join the car revolution. Join Beepi.
- Zendrive — Zendrive's Mobility Risk Intelligence (MRI) platform provides critical risk insights for smarter underwriting, claims, roadside assistance, driver analytics, and customer acquisition.
- BoomPop — Work culture resources, virtual event inspiration, team building ideas, and fresh perspectives on the future work, brought to you by the BoomPop team.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 78
- Round size: Series A $2.2M–$63M; Series B $17M–$135M; Series C $27M–$80M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Prexton Therapeutics — Voici la page d'accueil du site web
Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 90
- Round size: Series A $3.5M–$32M; Series B $4.1M–$30M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Vivici — Our mission is to meet the world's growing need for sustainable, nutritious and great tasting animal-free proteins.
- NutriLeads — NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more...Investment focus
- Industry: Software, SaaS, Biotechnology
- Stage:Seed, Series A
- Geography: Denmark, United Kingdom, Iceland
Investor stats
- Total investments: 29
- Round size: Seed $1.2M–$9.1M; Series A $5.6M–$22M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Tame — ABOUT With Tame you can fully customise your virtual events, and make them fun, engaging & exciting to attend.- Apply your branding: Customise your virtual event completely - Personalised Welcome: Personal welcome message when attendees enter - Multiple stages: Broadcast content across multiple stages. - Live streaming: Stream live via anybroadcasting software - Pre-recorded videos: Broadcast pre-recorded videos as if it was live - Breakout sessions: Enable public or private breakout sessions. - Virtual Sponsor booths: Allow attendees to engage with sponsors live. - Customise Chat: Allow for 1:1 chat, group chat or session chat. - 1:1 Video Meetings: Empower social networking virtually.OUR COMPANY We are an experience-centric company, and we believe in the power of great experiences. Our international group of dreamers, creators and rule-breakers passionate about merging design and technology together, enables us to transform that into one truly amazing event platform.OUR PEOPLE The team behind Tame has an aggregated decades long experience of creating events and building products that solve real problems for real people. So, what got us here? Our ambition to change a broken event industry through innovation, customer obsession and a relentless focus on the great experience.
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 425
- Round size: Series B $27M–$152M; Series C $40M–$200M; Post-IPO Equity $30M–$230M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
- Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
- ILiAD Biotechnologies —
PINC was launched as Paulig Incubator in 2018 to help Paulig stay in the forefront of relevant innovations, as well as to contribute to a tastier, healthier and more sustainable planet. Today, our ambition is the same, but we have developed into a corporate venture arm. We aim for strategic, financial, and societal impact in our investments,fostering a sustainable food system for tomorrow. We are investing across the agrifood value chain in three primary impact themes: Improve planetary health and diet within the current food system: This includes innovations in agriculture and food security, such as advanced crop breeding or green fertilizers, innovative ingredients and next generation healthy foods, as well as solutions for tracking and improving climate and nature. Novel technologies to feed 10 BN people by 2050: Technologies needed to sustainably produce enough food for our growing population. This includes food production without land use change, such as precision fermentation and cell-culture. A circular system for food & materials: Regardless of whether we grow our food in soil or in bioreactors, the system needs to be circular. Some examples are upcycled ingredients, food from unused sources, new coating and packaging solutions, as well as technologies to prevent or make better use of side streams. We are looking for entrepreneurs in an attractive market space with an intrinsic drive to find a solution to the problem they are addressing, a clear and scalable plan for success, a reliable team and partners whom we can trust and work closely with.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Coffee
- Stage:Seed, Pre-Seed, Series A
- Geography: Sweden, Denmark, United Kingdom
Investor stats
- Total investments: 18
- Round size: Seed $823k–$7M; Pre-Seed $549k–$2.8M; Series A $4.1M–$7.4M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Amatera — Amatera is a biotechnology research company that leverages the latest techniques in biotechnology, to create coffee varieties. Amatera urges to make coffee varieties more sustainable and climate resistant to fill that massive demand. Founded by Omar Dekkiche and Lucie Kriegshauser in 2022 and is located in Paris, France.
- Mycoverse — Mycoverse is a agri-biotech startup specializes in developing fungal-based biological crop protection solutions to replace chemical pesticides, targeting row crops with an initial focus on potato late blight.
- Win-Win — We're WNWN Food Labs and we love food. We're creating delicious, sustainable and ethical alternatives to unsustainable and ethically dubious foods. We're starting with cacao-free chocolate. Changing chocolate? It's Win-Win #alt-chocolate #altchocolate #alt-universe #altuniverse #alt-protein
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 121
- Round size: Series A $5.7M–$55M; Series B $14M–$88M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $209M in 2019
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Atlantic Labs supports and invests in mission-driven founders working on transformative technology ventures. <br><br>We partner with founders early, providing the capital, tools and network necessary to growing their companies and accompanying them on their entrepreneurial journey. We are currently active in areas including Digital Health, Future of Work, Machine Learning, Decentralized Networks, Mobility and Industrial Applications.
Show more...Investment focus
- Industry: Software, Health Care, Financial Services
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 194
- Round size: Seed $1.2M–$9.1M; Pre-Seed $850k–$3.8M; Series A $4.6M–$32M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Cluno — Cluno is an online car subscription service providing rental cars irrespective of any contracts. Cluno's digital car subscription challenges traditional car ownership models in the mobility market and expands the space between hourly and years-long commitments with a flexible option and transparent, fully predictable costs. The carsubscription is offered at a monthly package price, which covers almost all car-related costs such as maintenance, wear and tear, seasonal tires, warranty, registration, vehicle tax, insurance, and vehicle inspections. The minimum booking period is six months per vehicle. Subject to a notice period of three months, customers can change their vehicle after the minimum period, pause their car subscription, or continue on with their Cluno car indefinitely.
- bonify — Bonify, a Berlin based FinTech-Start-up, enables customers to benefit from their credit scoring and financial data. The company gives customers free and easy access to their credit score and let them upload additional relevant data. Then, it offers tools and personalized recommendations to help optimize the customer’s financial situation.Foundedin 2015 by key executives of McKinsey and Zalando, bonify has received significant funding from internationally leading VCs and successful entrepreneurs.
- tozero — Truly bringing lithium-ion battery waste tozero by recovering all critical matierlas, like lithium, nickel, cobalt, manganese, and graphite.
At Ugly Duckling Ventures, we make capital, know-how, and real-world application available to Nordic ventures at the seed & pre-seed stage. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Pre-Seed, Seed
- Geography: Denmark, Sweden, Finland
Investor stats
- Total investments: 16
- Round size: Seed $876k–$4.2M; Pre-Seed $917k–$1.7M
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- Eupry — Be in full control of your temperature compliance at all times. Collect temperature monitoring, mapping, and calibration in one GxP-compliant solution.
- Juristic — Juristic is the world's most advanced legal visualising tool - and it can automate legal drafting too! Solve complex legal and financial matters in real time. We are developing next-generation tools for advisers.
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Life Science
- Stage:Seed, Series A, Series B
- Geography: United States, France, Norway
Investor stats
- Total investments: 18
- Round size: Seed $5.7M–$21M; Series A $4M–$76M; Series B $23M–$108M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Commit Biologics — Add a description for facebook
- Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Nicholas Francis is Co-founder at framebunker
Show more...Investment focus
- Industry: SaaS, Robotics, Software
- Stage:Seed, Series A
- Geography: Denmark, United States
Investor stats
- Total investments: 4
- Round size: Seed $854k–$7.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Waterplan — Waterplan is a SaaS platform for companies to manage water availability in their facilities.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Grant, Pre-Seed, Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 87
- Round size: Seed $66k–$1.3M; Grant $22k–$1.1M; Pre-Seed $64k–$1.6M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Prezio — Prezio is an electricity tariff data API for Europe. We aggregate, structure, and serve real-time and historical electricity pricing data - spot prices, retail tariffs, and grid fees - so energy applications don't have to build and maintain that data infrastructure themselves. Typical customers are developers and product teams building EVsmart charging, heat pump control, home batteries, and solar optimization tools - anything that needs to know what electricity actually costs, right now or over time, across European markets.
- ENZIDIA — We crack the fundamental bottlenecks of enzyme engineering with unprecedented screening and data collection capacity
- Cacto Health — Cacto Health is the Developer of a medical device system designed for monitoring lymphedema in breast cancer patients.
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 12
- Round size: Series A $20M–$73M
- Lead/follow: 58% lead, 42% follow
- Last fund: Likely still investing — raised $143M in 2021
Portfolio highlights
- Henlez — Henlez is a Danish startup company.
- Synklino — Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
- Galecto — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 298
- Round size: Series A $6M–$65M; Series B $10M–$102M; Series C $11M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- protera — Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed.Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.
- Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
Unconventional Ventures invests in startups in the pre-seed and seed stage led by diverse founders identifying as women, people of color, immigrants and/or LGBTQ+, building scalable impact tech companies in the Nordics and beyond.
Show more...Investment focus
- Industry: Health Care, Software, Wellness
- Stage:Seed, Pre-Seed, Series A
- Geography: Sweden, United Kingdom, Denmark
Investor stats
- Total investments: 17
- Round size: Seed $1M–$5.2M; Pre-Seed $1.5M–$2.8M; Series A $4.8M–$18M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Flox Intelligence — Wildlife intelligence for critical infrastructure.
- AIRMO — Airmo is a space tech company that offers an independent data source that locates, quantifies, and tracks carbon dioxide and methane emissions through a small satellite constellation.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
Blue Horizon is accelerating the transition to a sustainable food system that delivers outstanding returns for the planet and people.
Show more...Investment focus
- Industry: Food and Beverage, Food Processing, Biotechnology
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 94
- Round size: Seed $2M–$12M; Pre-Seed $450k–$6.3M; Series A $2M–$28M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $187M in 2021
Portfolio highlights
- WOW EARN — Discover WOW EARN, the all-in-one Web3 app with crypto mining, multi-chain wallet, staking NFTs, and marketplace dApps. Join the global Web3 community today.
- EV Biotech — We design and optimise your precision fermentation strains and processes, tailored to your success.
- foodforecast — AI supported solution to reduce food waste.
Noon Ventures is a Copenhagen-based, early-stage venture investor established in 2020. We invest in proven transformative technologies with the potential to impact environmental or climate challenges.
Show more...Investment focus
- Industry: Biotechnology, AgTech, Farming
- Stage:Seed, Series A
- Geography: Denmark
Investor stats
- Total investments: 6
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
- Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.
- Lotus Microsystems — Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug andplay solutions enable our customers to innovate their electronics without worrying about power supply units.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!WE ARE AN EARLY-STAGE INVESTOR IN ONE OF THE MOST DYNAMIC AND ESSENTIAL FIELDS OF CURRENT HUMAN ENDEAVOR WE BRING ROBUST INVESTOR MUSCLE TO EARLY-STAGE VENTURES INVESTOR A specialized and focused investor Resources Powerful industry, substance and business resources Experience Wide networks and longstanding experience Team Yet, adaptability and speed of a lean, self-financed team
Show more...Investment focus
- Industry: Biotechnology, Health Care, Food and Beverage
- Stage:Series A, Seed, Series B
- Geography: United States, France, Denmark
Investor stats
- Total investments: 20
- Round size: Seed $3.3M–$20M; Series A $6.3M–$53M; Series B $24M–$50M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- uFraction8 — Multi-award-winning, innovative, microfluidics-based filter systems to provide bio-manufacturers with energy-efficient & ultra-scalable bioprocessing systems.
- Clever Carnivore — Clever Carnivore is a cell-cultured meat startup that uses stem cell biology, recombinant protein, and bioengineering to create cost-effective lab grown meats. With the company's high-efficiency model, cruelty-free, environmentally friendly, and cost-competitive technology it aims to produce sausage, burgers, and chicken nuggets.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 182
- Round size: Series A $3.7M–$87M; Series B $15M–$114M; Series C $22M–$115M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
- Spero Therapeutics — Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.
- Constellation Pharmaceuticals — Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
Steen Riisgaard
Show more...Investment focus
- Industry: Life Science, Therapeutics, Biotechnology
- Stage:Pre-Seed
- Geography: Denmark
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 193
- Round size: Series A $3.1M–$33M; Series B $6.7M–$55M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $222M in 2019
Portfolio highlights
- nyra health — myReha is an artificial intelligence and evidence-based neurological research tablet app that offers a revolutionary form of therapy. myReha was founded in 2020 and was headquartered in Vienna, Austria.
- UroMems — The device is developing an active implantable medical device based on the cutting edge technologyl in the field of embedded systems and micro-technologies for the development of its products.
- Heliatek — As the technology leader in organic photovoltaics, Heliatek develops, produces and distributes industrial-grade organic PV solar solutions for virtually any building surface (horizontal, vertical, curved, rigid, and flexible). Heliatek stands for energy solutions designed for various traditional and never been possible before applications based onits unique features – it is ultra-light, flexible and truly green. HeliaSol® is a ready-to-use solution, ideal for retrofitting on existing building structures. HeliaFilm® is tailor-made solar film for companies in the building and construction material industry, to integrate into their façade or roof system products. Heliatek currently employs about 160 people at the Dresden and Ulm locations in Germany.The Free State of Saxony, the Federal Republic of Germany, and the European Union funded research and development, as well as the installation of the production technology.
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 65
- Round size: Series A $10M–$50M; Series B $20M–$95M; Series C $16M–$53M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- Notify Therapeutics — Notify Therapeutics develops therapies for the treatment of infertility. By targeting the early and hormone-independent phase of egg maturation, the company aims at developing a first-in-class treatment for infertile women, who do not benefit from standard hormone therapy. It utilizes drug-inducing factors that regulate the intracellular AKTpathway and target the early and hormone-independent phase of egg maturation for the treatment.
Giampaolo’s aim has always been to apply a disruptive approach to functional food ingredients and that’s how he founded Italiana Ingredienti in ’89 and Campus in ’05. Both companies have been acquired, Italiana Ingredienti by Chr. Hansen in ‘99 and Campus by Firmenich in ’18. Today he serves as Founder and Chairman at Hi-Food, an Italian companyproviding key functional ingredients to food companies, and as a business Angel Investor in several startups.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Plant-Based Foods
- Stage:Seed, Pre-Seed
- Geography: Italy, Denmark
Investor stats
- Total investments: 3
- Round size: Seed $4.2M–$7.8M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
- Dreamfarm — We are a team of food-lovers 100% made in Italy! We dreamt of a better, tastier, more sustainable future and decided to join forces to create something special.
Mr. Linton is the founder of Canopy Growth Corporation (CGC) and co-founder of Tweed Marijuana Inc.Bruce’s primary focus has been to position cannabis brands in a competitive market and to raise the capital necessary to fund such operations. Bruce’s experience as a founder, CEO, and Board member across a wide variety of enterprises has influencedthe positive start of Canopy Growth, which to date has enjoyed market support for capital raises of over $150 million and the distinction of being the first company in the industry to be offered debt instruments by a federal lender. Bruce has led three M&A transactions valued over $500 million total since founding CGC. In addition to his leadership responsibility at Canopy Growth, Bruce is the CEO of communications company Martello Technologies. After beginning his career at Newbridge Networks Corporation, he has since held positions that include General Manager and Re-Founder of Computerland.ca, President and Co-Founder of webHancer Corp, and part of the establishing team at CrossKeys Systems Corporation. He was also part of the leadership team for the NASDAQ/TSX initial public offering at CrossKeys. Bruce has been responsible for the acquisition and/or disposition of over $600 million in business assets, and has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He is the past Chairman of the Ottawa Community Loan Foundation, past Board Member and Treasurer of Canada World Youth past Board of Governor for Carleton University, past President of the Nepean Skating Club and past President of the Carleton University Students Association.
Show more...Investment focus
- Industry: Cannabis, Health Care, Biotechnology
- Stage:Post-IPO Equity, Seed, Pre-Seed
- Geography: Canada, United States, Denmark
Investor stats
- Total investments: 8
- Round size: Seed $1.8M–$5M; Post-IPO Equity $37k–$53M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Omura — Discover heat-not-burn technology with Omura's dry herb vaporizer devices. Explore sustainable vaping options for hemp & whole flower CBD.
- MindMed — MindMed discovers, develops, and deploys psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering. Learn more about our medicines and therapies today.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1475
- Lead/follow: no public data
Portfolio highlights
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
- Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators
They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.
Show more...Investment focus
- Industry: Software, Information Technology, B2B
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, India
Investor stats
- Total investments: 24
- Round size: Seed $147k–$2.4M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Ulobby — Ulobby is an automated tool for stakeholder management and political monitoring
- Mechanic Miner — Mechanic Miner is a 2D construction/survival game with mechanical steam-powered machines. You are stranded on a strange and forbidding planet, where survival is made difficult by hostile animals and plant life. From your home world you did bring a multitool, which is able to craft any kind of machine part - provided the requisite rawmaterials can be found. Relying solely on the technology you brought, you set out to explore a whole world. You can progress through the game by acquiring new types of steam-powered technology elements, that are necessary to delve deeper into the diverse biomes of the planet, and perhaps, ultimately, discover the means to escape. You can construct any kind of machine of your own design - and any kind of machine can be simulated by the game's physics engine - and of course, designs can be shared with your friends.
- ResoTher Pharma — ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 230
- Lead/follow: no public data
Portfolio highlights
- Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
- tozero — Truly bringing lithium-ion battery waste tozero by recovering all critical matierlas, like lithium, nickel, cobalt, manganese, and graphite.
- Orakl Oncology — Cultivated with love by the Orakl team.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. We're able to select the promising companies
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Chemical
- Stage:Series A, Series B
- Geography: United Kingdom, Austria, Belgium
Investor stats
- Total investments: 18
- Lead/follow: no public data
Portfolio highlights
- Orphazyme — Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
- Avantium — Build a sustainable future with Avantium. Leading the change in green chemistry and innovative solutions.
- F-Star Therapeutics — F-star is a clinical stage biotech developing next generation immunotherapies to transform the lives of patients with cancer. We are developing transformational cancer immunotherapies for patients who have few remaining options.
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Series A, Seed
- Geography: Sweden, United States, Denmark
Investor stats
- Total investments: 161
- Lead/follow: no public data
Portfolio highlights
- Fibbl — Fibbl is the world's first cost-effective end-to-end solution for 3D and AR focused visual marketing. Integrate 3D & AR into e-commerce and marketing in minutes.Fibbl have industrialized the process of producing photorealistic 3D models for consumer products from global brands. Fibbl has the world's largest 3D model database forconsumer products.Learn more - https://www.fibbl.com/
- Agteria Biotech — Agteria Biotech is an innovative biotech startup dedicated to mitigating methane emissions in cattle through our groundbreaking compound. By promoting sustainable practices in livestock farming, we aim to engage investors and dairy companies interested in eco-friendly solutions. Partner with us to t
- Senseworks — Senseworks is an insight platform that enables colleagues to collaborate effectively with customers by providing a single source of truth for accounting data.
The Yield Lab Europe is a €55m early stage Agrifood and Ag Tech fund which comprises an accelerator and a larger follow-on fund, investing in high tech companies with the potential to significant disrupt and improve our current systems of global food production, and to improve the environmental sustainability of the industry. The main fund invests€1m each into 10-12 companies over several follow on rounds, with the strongest accelerator companies expected to progress to the main fund. The Yield Lab Europe is also part of a global network of Agrifood Tech funds, with global headquarters in St Louis USA, and sister funds in LATAM and Singapore.
Show more...Investment focus
- Industry: AgTech, Agriculture, Biotechnology
- Stage:Seed, Series A
- Geography: Ireland, France, United Kingdom
Investor stats
- Total investments: 36
- Round size: Seed $531k–$3M; Series A $2.1M–$10M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely still investing — raised $52M in 2021
Portfolio highlights
- BBLeap — BBLeap is a company that operates in the manufacturing industry, specifically focusing on the agricultural sector. The company's main offering is the LeapBox system, a modular solution that can be attached to any new or used sprayer. This system is designed to enhance the efficiency and effectiveness of crop spraying, addressing the issue ofover-application and weak spots in fields. BBLeap's approach, termed 'Farming On Plant Level', aims to consider individual plant needs and environmental factors such as soil conditions and weather. The company's vision is to provide better spraying equipment to the agricultural sector, contributing to more sustainable and precise farming practices.
- BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
- Marama Labs — Marama Labs provides an integrated chemical analysis platform that empowers customers to optimize their production processes and match their products and brands to customer needs, with ease.
+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, Switzerland, Denmark
Investor stats
- Total investments: 58
- Lead/follow: no public data
Portfolio highlights
- Vandria — At the vanguard of Mitochondrial research
- Constructive Bio — Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
Northzone is a multi-stage venture capital fund that seeks to invest in the healthcare, semiconductors, software, hardware, artificial intelligence, blockchain, and gaming industries.
Show more...Investment focus
- Industry: Software, Information Technology, E-Commerce
- Stage:Series A, Series B, Seed
- Geography: United States, Sweden, United Kingdom
Investor stats
- Total investments: 278
- Lead/follow: no public data
Portfolio highlights
- Nivoda — Nivoda provides jewellery businesses with a simple solution to strengthen profits, increase efficiency and accelerate growth with its B2B diamond marketplace. Designed to save you time and money whilst giving you access to the world’s diamond supply at the best prices with zero inventory risk, Nivoda is trusted by thousands of retailers all overthe globe.
- Tana — Tana is a software development company that reinvents how humans, teams, and computers work together. Tana was founded in 2020 and was headquartered in Oslo, Norway.
- Berry Street — Nutrition therapy by registered dietitians covered by insurance.
Dawn Biopharma is a global investment firm of KKR.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Seed, Series A, Series B
- Geography: Denmark, France, Belgium
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Bambusa Therapeutics — Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 79
- Round size: Series A $8.5M–$74M; Series B $14M–$75M; Series C $13M–$143M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- PanOptica — PanOptica is a biopharmaceutical company developing a topical eye drop for the treatment of eye diseases caused by abnormal or leaky blood vessels.
- Galera Therapeutics — Developing novel therapies that have the potential to reduce radiotherapy-induced toxicities and improve the anti-cancer efficacy of radiation therapy
- Reneo Pharmaceuticals — OnKure Therapeutics - Writing the Next Chapter in Precision Medicines for Patients With Cancer
In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Series A, Series B, Series C
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 340
- Lead/follow: no public data
Portfolio highlights
- Agave Games — Agave Games is a mobile games publishing company and provides unique experiences
- Grand Games — Grand Games is shaping the future of gaming by creating genre-defining games played by millions worldwide.
- Lindus Health — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
We invest in disruptive and encouraging Agri-Food tech and Food Loss companies, reshaping our food systems in order to solve the current & future problems of production.
Show more...Investment focus
- Industry: Biotechnology
- Stage:Seed
- Geography: Denmark
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Yeastup — Yeastup transforms brewer's yeast into proteins & fibers for food & supplements. Contact us for sustainable ingredient solutions.
- New School Foods — Salmon, made from plants. Clean label with ALL the Omega-3s, NONE of the mercury. Made in Canada.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 542
- Round size: Seed $909k–$6.5M; Series A $3M–$33M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- Sdui — Sdui is the solution for mobile communication in schools. With amazingly easy features for messaging, timetables and a wide range of third party integrations, the app digitizes processes and reduces administrative effort. Within two years, Sdui has reached hundreds of institutions and grown a serious reputation in the educational market.
- envelio — We are driving forward the energy transition with our smart grid solutions for grid operators. Get information now and plan smart!
- Atriva Therapeutics — Therapies against viral infections. First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Denmark investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 investors investing in Denmark Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!